JP2018529756A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529756A5
JP2018529756A5 JP2018525517A JP2018525517A JP2018529756A5 JP 2018529756 A5 JP2018529756 A5 JP 2018529756A5 JP 2018525517 A JP2018525517 A JP 2018525517A JP 2018525517 A JP2018525517 A JP 2018525517A JP 2018529756 A5 JP2018529756 A5 JP 2018529756A5
Authority
JP
Japan
Prior art keywords
composition
patient
antagonist
treatment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018525517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/044528 external-priority patent/WO2017023699A1/en
Publication of JP2018529756A publication Critical patent/JP2018529756A/ja
Publication of JP2018529756A5 publication Critical patent/JP2018529756A5/ja
Priority to JP2021198768A priority Critical patent/JP7386838B2/ja
Priority to JP2023150185A priority patent/JP7691464B2/ja
Priority to JP2025089860A priority patent/JP2025128207A/ja
Pending legal-status Critical Current

Links

JP2018525517A 2015-07-31 2016-07-28 ヘプシジン媒介性障害を治療するための方法 Pending JP2018529756A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021198768A JP7386838B2 (ja) 2015-07-31 2021-12-07 ヘプシジン媒介性障害を治療するための方法
JP2023150185A JP7691464B2 (ja) 2015-07-31 2023-09-15 ヘプシジン媒介性障害を治療するための方法
JP2025089860A JP2025128207A (ja) 2015-07-31 2025-05-29 ヘプシジン媒介性障害を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562199434P 2015-07-31 2015-07-31
US62/199,434 2015-07-31
US201562268788P 2015-12-17 2015-12-17
US62/268,788 2015-12-17
PCT/US2016/044528 WO2017023699A1 (en) 2015-07-31 2016-07-28 Methods for treating hepcidin-mediated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021198768A Division JP7386838B2 (ja) 2015-07-31 2021-12-07 ヘプシジン媒介性障害を治療するための方法

Publications (2)

Publication Number Publication Date
JP2018529756A JP2018529756A (ja) 2018-10-11
JP2018529756A5 true JP2018529756A5 (https=) 2019-08-29

Family

ID=57886392

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018525517A Pending JP2018529756A (ja) 2015-07-31 2016-07-28 ヘプシジン媒介性障害を治療するための方法
JP2021198768A Active JP7386838B2 (ja) 2015-07-31 2021-12-07 ヘプシジン媒介性障害を治療するための方法
JP2023150185A Active JP7691464B2 (ja) 2015-07-31 2023-09-15 ヘプシジン媒介性障害を治療するための方法
JP2025089860A Pending JP2025128207A (ja) 2015-07-31 2025-05-29 ヘプシジン媒介性障害を治療するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021198768A Active JP7386838B2 (ja) 2015-07-31 2021-12-07 ヘプシジン媒介性障害を治療するための方法
JP2023150185A Active JP7691464B2 (ja) 2015-07-31 2023-09-15 ヘプシジン媒介性障害を治療するための方法
JP2025089860A Pending JP2025128207A (ja) 2015-07-31 2025-05-29 ヘプシジン媒介性障害を治療するための方法

Country Status (17)

Country Link
US (3) US20170029499A1 (https=)
EP (2) EP3888752A1 (https=)
JP (4) JP2018529756A (https=)
KR (2) KR102889430B1 (https=)
CN (3) CN108026582A (https=)
AU (2) AU2016302768B2 (https=)
BR (1) BR112018001853A2 (https=)
CA (2) CA2991637C (https=)
EA (1) EA201890185A1 (https=)
ES (1) ES2877708T3 (https=)
IL (2) IL256615B (https=)
MX (1) MX2018000778A (https=)
NZ (1) NZ739392A (https=)
SG (1) SG10201913062SA (https=)
TW (3) TW202043482A (https=)
WO (1) WO2017023699A1 (https=)
ZA (1) ZA202003889B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
EP3735421A4 (en) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
CN111217819B (zh) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 乌帕替尼的合成方法
JP7701273B2 (ja) 2019-05-01 2025-07-01 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
CN114375205A (zh) * 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20220107252A (ko) 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
CN115243762A (zh) * 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
EP4142721A1 (en) * 2020-04-29 2023-03-08 Bioage Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
TWI907583B (zh) * 2020-12-11 2025-12-11 大陸商江蘇恒瑞醫藥股份有限公司 Jak抑制劑在腎臟疾病中的應用
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN113502325B (zh) * 2021-07-02 2024-09-10 厦门市妇幼保健院(厦门市优生优育服务中心、厦门大学附属妇女儿童医院、厦门市林巧稚妇女儿童医院) 用于孕期铁营养缺乏风险评估检测试剂盒与应用方法
JP2024540480A (ja) 2021-11-17 2024-10-31 ディスク・メディシン・インコーポレイテッド 腎臓疾患の貧血を処置する方法
AU2023283829A1 (en) * 2022-06-09 2024-11-07 Disc Medicine, Inc. Methods for treating blood loss conditions
EP4615867A1 (en) * 2022-11-11 2025-09-17 Tourmaline Bio, Inc. Methods for the treatment of cardiovascular disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808194A (en) 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
JP4960096B2 (ja) * 2003-09-22 2012-06-27 ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−６の生物学的効果を減じる化合物の使用
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
JP2008529968A (ja) * 2005-02-08 2008-08-07 国立循環器病センター総長 インスリン様成長因子−１（ｉｇｆ−１）を使用する慢性重症心不全を処置するための新規方法
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
US7820790B2 (en) * 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
AR058135A1 (es) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
KR20110112307A (ko) * 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
KR101913109B1 (ko) * 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
FR2978964B1 (fr) * 2011-08-09 2015-02-20 Conservatoire Nat Arts Composition vaccinale anti-il-6
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
CN104768578A (zh) * 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
CN104903349B (zh) 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US20160130340A1 (en) 2013-10-07 2016-05-12 Alderbio Holdings Llc Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis
US9139648B1 (en) * 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료

Similar Documents

Publication Publication Date Title
JP2018529756A5 (https=)
JP2015533787A5 (https=)
TWI653339B (zh) 用於治療海帕西啶（ｈｅｐｃｉｄｉｎ）介導之病症之方法
CN111182919A (zh) 抗cd137抗体
JP2020513788A5 (https=)
US10118967B2 (en) Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies
Phillips et al. Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton's tyrosine kinase inhibitor (BTKi) therapy
JP7304287B2 (ja) 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
JP2024038034A (ja) 膀胱癌の抗ｐｄ－ｌ１抗体治療
TW201734041A (zh) 抗ｉｌ-１７ｃ抗體
US20250179168A1 (en) Materials and methods for treating stress-related disorders and cancer
Zhang et al. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis
Mukhtorov WAY TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS WITH GENETIC ENGINEERED BIOLOGICAL DRUGS
JP2019521160A5 (https=)
KR20240146675A (ko) Egfr/met 이중특이성 항체로 치료받은 환자에서 주입-관련 반응을 감소시키기 위한 방법
AU2024337472A1 (en) Methods of treating non-small cell lung cancer
JP2023520515A5 (https=)
JP2018520990A (ja) 抗ｆｇｆｒ４抗体および胆汁酸捕捉剤の組み合わせ
JP2023550310A (ja) 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト
Wang et al. A study on inhibition of inflammation via p75TNFR signaling pathway activation in mice with traumatic brain injury
JP2022520817A5 (https=)
WO2021214905A1 (ja) 抗ヒトＦｎ１４抗体と免疫チェックポイント阻害剤を併用することにより、がんを予防又は治療する医薬組成物及び方法
WO2025148900A1 (en) Combination therapy of grem1 antagonist and activin receptor antagonist for treating pah
TWI825687B (zh) 抗ｃｘｃｒ２抗體及其用途
US20260102490A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma